Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Sign up freePricing

Omega Fund Vii, L.P. investment portfolio

Omega Fund Vii, L.P. has made numerous investments in companies such as Artios Pharma, Nrg Therapeutics, and Eyebiotech within the Healthcare & Life Sciences sector.

vc
Portfolio
3
Team
0

Portfolio (3)

CompanySectorCitySourceLast confirmed on
Artios Pharma Limited
Artios Pharma Limited develops DNA‑damage‑response‑based cancer therapeutics. Its pipeline includes the ATR inhibitor alnodesertib and the Polθ inhibitor ART6043, targeting hard‑to‑treat solid tumours.
Healthcare & Life SciencesCambridgeConfirmed2025-12-28
Eyebiotech Limited
Eyebiotech Limited is a London‑based biotechnology company that develops therapeutic treatments for ophthalmological diseases, focusing on retinal conditions. Its products target patients requiring advanced eye‑disease therapies.
Healthcare & Life SciencesLondonConfirmed2025-07-08

Sign up to see the full portfolio

+1 more company

Sign up

Shareholding changes (4)

Omega Fund Vii, L.P.'s positions across portfolio companies
2026
  • 04-04ChangedNrg Therapeutics Ltd
    • SERIES A2 2,419,355 → 0
    • SERIES A2 (FULLY PAID UP) 0 → 3,024,194
    • SERIES B 0 → 1,516,129
2025

Sign up free to see when this investor has bought or sold shares.

+2 more changes

Sign up